OncoTect for Taxanes in Early-Stage Breast Cancer
Early-Stage Breast Cancer
Clinical ValidationActive
Key Facts
About Aida Oncology
Aida Oncology is a private, pre-revenue diagnostics company leveraging machine learning on RNA expression data to predict chemotherapy efficacy, starting with taxanes in breast cancer. The company has presented multiple clinical validation studies at major conferences (ESMO 2025, SABCS) for its multigene signatures. Its business model targets the large, underserved market of chemotherapy selection, aiming to reduce ineffective treatments and improve patient outcomes.
View full company profileTherapeutic Areas
Other Early-Stage Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| MammaPrint/BluePrint Clinical Utility Expansion | Agendia | Commercial |
| Real-World Evidence (FLEX Study) | Agendia | Observational Study |
| Pathlight MRD Test | SAGA Diagnostics | Commercial |
| GammaPod Commercialization & Clinical Adoption | Xcision Medical Systems | Commercial |
| Signatera™ MRD (Adjuvant De-escalation) | Natera | Clinical Utility Study |